SILENCE THERAPEUTICS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-01-01

Employees: -

Market Cap: $889.1M

Website: http://www.silence-zone.com/

Clinical Trials

Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Phase 2

Completed

Conditions: Lipoprotein(a)
Atherosclerosis
Cardiovascular Diseases

Interventions: Drug: Placebo
Drug: SLN360

First Posted Date: 2022-09-13

Last Posted Date: 2024-07-31

Lead Sponsor: Silence Therapeutics plc

Target Recruit Count: 180

Registration Number: NCT05537571

Locations: 🇬🇧
Completed, London, United Kingdom

Study to Assess SLN124 in Patients With Polycythemia Vera

Phase 1

Recruiting

Conditions: Polycythemia Vera

Interventions: Drug: SLN124
Drug: Placebo

First Posted Date: 2022-08-12

Last Posted Date: 2024-04-22

Lead Sponsor: Silence Therapeutics plc

Target Recruit Count: 65

Registration Number: NCT05499013

Locations: 🇵🇱
PRATIA Hematologia Sp. z o. o., Katowice, Poland
🇲🇾
Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia
🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia

and more 20 locations

A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Non-transfusion-dependent Thalassemia
Low Risk Myelodysplastic Syndrome
Very-Low Risk Myelodysplastic Syndrome

Interventions: Drug: Placebo
Drug: SLN124

First Posted Date: 2021-01-22

Last Posted Date: 2024-01-03

Lead Sponsor: Silence Therapeutics plc

Target Recruit Count: 44

Registration Number: NCT04718844

Locations: 🇲🇾
Sarawak General Hospital, Kampung Sarawak, Malaysia
🇹🇭
King Chulalongkorn Memorial Hospital, Bangkok, Thailand
🇹🇭
Mahidol University - Faculty of Medicine - Ramathibodi Hospital, Bangkok, Thailand

and more 17 locations

Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

Phase 1

Completed

Conditions: Hyperlipidemias
Dyslipidemias
Elevated Lp(a)

Interventions: Drug: SLN360
Drug: Placebo

First Posted Date: 2020-10-28

Last Posted Date: 2024-08-12

Lead Sponsor: Silence Therapeutics plc

Target Recruit Count: 70

Registration Number: NCT04606602

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States
🇺🇸
Jacksonville Center for Clinical Research Ltd., Jacksonville, Florida, United States

and more 5 locations

A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

Early Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: SLN124
Drug: Placebo

First Posted Date: 2020-09-23

Last Posted Date: 2023-04-21

Lead Sponsor: Silence Therapeutics plc

Target Recruit Count: 24

Registration Number: NCT04559971

Locations: 🇬🇧
Hammersmith Medicines Research, London, United Kingdom

Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124

Phase 1

Withdrawn

Conditions: Low Risk Myelodysplastic Syndrome
Non-transfusion-dependent Thalassemia

Interventions: Drug: SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo

First Posted Date: 2019-11-25

Last Posted Date: 2020-04-27

Lead Sponsor: Silence Therapeutics plc

Registration Number: NCT04176653

Locations: 🇧🇬
MHAT Dr. Nikola Vasiliev AD, Kyustendil, Bulgaria
🇧🇬
Medical Center COMAC MEDICAL, Sofia, Bulgaria
🇧🇬
UMHAT Sv. Ivan Rilski, Sofia, Bulgaria

and more 2 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy